Health
Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies – News-Medical.Net
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-ca…
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.
According to WHO reports, the current COVID-19 (coronavirus disease 2019) pandemic has caused more…
-
Noosa News20 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News22 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General19 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win
-
Noosa News19 hours agoFranz Ferdinand: Australian Tour 2025